NCT05068752View on ClinicalTrials.gov

Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 28, 2021

Primary Completion Date

October 30, 2024

Study Completion Date

December 30, 2024

Conditions
Pancreas Cancer
Interventions
DRUG

Vemurafenib

Vemurafenib 480 mg PO BID daily given with Sorafenib 200 mg PO BID

DRUG

Sorafenib

Sorafenib 200 mg PO BID and Vemurafenib 480 mg PO BID daily

Trial Locations (1)

85258

HonorHealth Research Institute, Scottsdale

Sponsors

Collaborators (2)

Bayer
Genentech, Inc.
All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

HonorHealth Research Institute

OTHER